Compare Regeneron Pharmaceuticals Inc (REGN) vs Workday Inc (WDAY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Workday (WDAY) trades at $187.81, up 0.68% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $8.45B in 2025 to $10.2B projected for 2026, with net income margin improving to 12.31%. Recent developments include UAE market expansion and AI product launches, though layoffs and a fraud investigation present headwinds. Analyst consensus remains positive with a $202.92 price target.

WDAY's valuation appears stretched with a P/E of 37.53, but robust AI-driven growth and strategic partnerships support long-term upside. Key risks include integration execution, competitive pressures, and ongoing legal scrutiny. The stock offers growth exposure with moderate risk for investors comfortable with premium valuations.